A psychedelics-focused drug development company is officially asking the Food and Drug Administration (FDA) to review an application to approve MDMA as a prescription medication for the treatment of post-traumatic stress disorder (PTSD).

The MAPS Public Benefit Corporation (MAPS PBC) announced on Tuesday that it submitted the new drug application (NDA) to FDA, requesting an expedited review given that the agency previously designated the psychedelic as a breakthrough therapy.

FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD

H/T: The Most Revolutionary Act

The MAPS Public Benefit Corporation is subsidiary of Multidisciplinary Association for Psychedelic Studies. MAPS was founded by Rick Doblin.*

Related:

Read More »